Biomaterial-assisted cell therapy in osteoarthritis: From mesenchymal stem cells to cell encapsulation

Abstract : Osteoarthritis (OA) is a degenerative and inflammatory joint disease that affects the cartilage, subchondral bone, and joint tissues. Although current drug therapies can provide a degree of symptomatic relief from pain, they fail to prevent joint damage. Mesenchymal stem/stromal cells (MSCs) have generated significant interest in terms of medical applications because they exert their therapeutic properties by secretion of bioactive factors that have potent immunomodulatory, antiapoptotic, antifibrotic, and anti-inflammatory effects. However, intra-articular injection of MSCs has major limitations including cell death upon injection and massive leakage from the injection site. Encapsulation of MSCs has therefore been developed as a way to overcome these limitations and to deliver therapeutic bioactive factors in several pathologies. In this review, we first briefly highlight the main therapeutic properties of MSCs and their applications in OA treatment. We then focus on MSC encapsulation and the current advances this strategy offers for the treatment of OA.
Complete list of metadatas

Cited literature [87 references]  Display  Hide  Download

https://www.hal.inserm.fr/inserm-01844461
Contributor : Valérie Pecqueret <>
Submitted on : Thursday, July 19, 2018 - 1:36:30 PM
Last modification on : Friday, April 5, 2019 - 1:16:35 AM
Long-term archiving on : Saturday, October 20, 2018 - 3:12:42 PM

File

 Restricted access
To satisfy the distribution rights of the publisher, the document is embargoed until : jamais

Please log in to resquest access to the document

Identifiers

Collections

Citation

Fahd Hached, Claire Vinatier, Catherine Le Visage, Henri Gondé, Jérôme Guicheux, et al.. Biomaterial-assisted cell therapy in osteoarthritis: From mesenchymal stem cells to cell encapsulation. Best Practice and Research: Clinical Rheumatology, Elsevier, 2018, pp.1-16. ⟨10.1016/j.berh.2018.05.002⟩. ⟨inserm-01844461⟩

Share

Metrics

Record views

319